Vanguard Capital Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
Vanguard Capital Management's BEAM Position: Q3 2026 in Review
Vanguard Capital Management increased its Beam Therapeutics (BEAM) stake by 0.19% in Q3 2026, buying an estimated $246K and bringing the position to 4,608,292 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1459.
Vanguard Capital Management first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $158M in Q2 2026. 262 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Vanguard Capital Management held 4,608,292 shares of Beam Therapeutics worth $113M as of Q3 2026.
- Vanguard Capital Management bought 8,855 Beam Therapeutics shares in Q3 2026, an estimated $246K.
- Beam Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1459 holding.
- Vanguard Capital Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Beam Therapeutics position peaked at $158M in Q2 2026.
- 262 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.